NCT03214510 2026-03-05
Thoracic Epidural Analgesia or Four-Quadrant Transversus Abdominus Plane Block in Reducing Pain in Patients Undergoing Liver Surgery
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
Clinical Trials
25 trialsNCT06525740 2026-03-04
Methadone Versus Intrathecal Hydromorphone for Postoperative Pain Relief in Gynecologic Cancer Undergoing Surgery
Mayo Clinic
Phase 4 Recruiting
NCT06411795 2026-02-03
Rectus Sheath Block With Liposomal Bupivacaine Versus Thoracic Epidural Analgesia for Pain Control Following Pancreatoduodenectomy
Masonic Cancer Center, University of Minnesota
Phase 2 Recruiting
NCT07315022 2026-01-02
Enhanced Recovery After Surgery-Based Multimodal Preemptive Analgesia for Perioperative Management in Transarterial Chemoembolization of Intermediate-to-Advanced Hepatocellular Carcinoma
First Affiliated Hospital, Sun Yat-Sen University
Phase 4 Completed
NCT04296305 2025-12-26
Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain
M.D. Anderson Cancer Center
Phase 4 Active not recruiting
NCT06940570 2025-10-23
MATCH
University of Texas Southwestern Medical Center
Phase 3 Suspended
NCT05842044 2025-09-05
No-PAIN
University of Miami
Phase 2 Recruiting
NCT03579446 2025-08-03
Levorphanol as a Second Line Opioid in Reducing Pain in Patients With Cancer
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT04785768 2025-05-22
IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration
Fujian Cancer Hospital
Phase 3 Completed
NCT02423876 2023-09-06
Epidural Anesthesia Within an Enhanced Recovery Pathway in Reducing Pain in Patients Undergoing Gynecologic Surgery
University of Wisconsin, Madison
Phase 3 Completed
NCT05848635 2023-05-08
Hydromorphone for Perioperative Analgesia in Lung Tumor Ablation Parallel Controlled
Qianfoshan Hospital
Phase 4 Unknown
NCT03564548 2021-07-28
REBORN
Tetra Bio-Pharma
Phase 2 Unknown
NCT01812759 2021-06-29
Fentanyl for Breakthrough Pain in the Emergency Department
M.D. Anderson Cancer Center
Phase 4 Terminated
NCT02459964 2021-06-16
Compare Fentanyl Nasal Spray With Intravenous Opioids to Treat Severe Pain
M.D. Anderson Cancer Center
Phase 4 Completed
NCT03375515 2021-03-08
PCA vs Non-PCA Intravenous Hydromorphone Titration for Severe Cancer Pain
Fujian Cancer Hospital
Phase 3 Completed
NCT04613869 2020-11-03
The Effect of Esketamine on Patients Undergoing Tumor Surgery
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase NA Unknown
NCT00305110 2018-08-20
Safety of Hydromorphone in Adult Patients Presenting to the Emergency Department With Acute Severe Pain
Montefiore Medical Center
Phase 2 Completed
NCT02958566 2017-03-20
Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
University of Illinois College of Medicine at Peoria
Phase 4 Unknown
NCT02461056 2015-06-03
Synergistic Effect of Ibuprofen and Hydromorphone for Postoperative Pain
Samsung Medical Center
Phase NA Completed
NCT01824524 2014-08-15
A Pharmacokinetic and Safety Study of Osmotic Release Oral System (OROS) Hydromorphone in Non-Opioid Tolerant Chinese Participants With Cancer
Xian-Janssen Pharmaceutical Ltd.
Phase 1 Completed
NCT02084355 2014-03-12
Study of Opioid Rotation Versus Opioid Escalation in Patients With Moderate to Severe Cancer Pain
Gyeongsang National University Hospital
Phase 3 Unknown
NCT01205126 2014-02-03
An Efficacy and Safety Study of Oral Osmotic Therapeutic System (OROS) Hydromorphone Hydrochloride (HCl) in Participants With Cancer Related Pain
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 3 Completed
NCT01648699 2013-10-11
Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain
Janssen Pharmaceutica
Phase 4 Terminated
NCT00003115 2011-02-23
Epidural Hydromorphone Compared With Hydromorphone Infusion in Treating Patients With Prostate Cancer Undergoing Radical Prostatectomy
Roswell Park Cancer Institute
Phase 3 Completed
NCT00822614 2009-01-14
FINDS
Akela Pharma, Inc.
Phase 3 Unknown